the catch-up campaign have been published [2, 3] . The vaccine was licensed on the basis of immunogenicity data alone, without evidence of protection from an efficacy trial. A program of enhanced surveillance to evaluate the epidemiologic impact of the vaccination program was therefore established [4] .
We describe here the investigation of the serologic response to meningococcal serogroup C (MenC) disease in subjects with vaccine failure and unvaccinated subjects to inform future immunization strategy. Primary failure is lack of an initial response to the vaccine such that the vaccinee remains susceptible, whereas secondary failure is occurrence of disease despite an initial response and would be manifest as waning protection at the population level. The latter mechanism is suggested by postlicensure surveillance of MenC disease in England, which shows that, although the efficacy of MCC vaccine is high in the first year after immuni- zation in all age groups, it declines thereafter, most markedly in those vaccinated in infancy, although the number of cases remains small because of herd immunity [5] . The demonstration of waning efficacy was surprising, because the ability of MCC vaccine to induce immunologic memory for at least 4 years after vaccination in infancy [6] was predicted to provide long-term protection against disease, and has called into question the value of using immunologic memory as a correlate of long-term protection. In this article, we seek to confirm this finding by investigating the serologic responses to disease in vaccinated subjects with MenC disease for evidence of immune memory as a marker of secondary vaccine failure. Clinical and immunologic risk factors that might predispose to vaccine failure were also investigated.
SUBJECTS, MATERIALS, AND METHODS
Case ascertainment. Surveillance of laboratory-confirmed meningococcal disease in England and Wales is based on laboratory isolates of Neisseria meningitidis referred to the Meningococcal Reference Unit (MRU) of the Health Protection Agency (HPA) for phenotyping and on blood or cerebrospinal fluid samples sent to the MRU for detection and genogrouping of meningococci by polymerase chain reaction (PCR) [7] , which has been established at the MRU since 1997 [8] . A similar system of surveillance exists in Northern Ireland, and laboratory isolates are also referred to the MRU. The serogroup and serosubtype of clinical isolates are identified using monoclonal antibodies [8] . Acute and convalescent clotted-blood samples for meningococcal serologic testing are also requested from the attending clinician. A laboratory-confirmed case of MenC disease is defined as clinical meningococcal disease in which the serogroup C organism was cultured from a sterile site, rash aspirate, or throat swab or in which a blood sample was PCR positive for both meningococci and genogroup C. The vaccination status of subjects with laboratory-confirmed meningococcal serogroup C Selection of control subjects. An equal number of unvaccinated subjects with MenC disease from the same time period as the subjects with vaccine failure were selected as control subjects, on the basis of the availability of stored serum samples. Acute and convalescent responses to MenC disease and other immunologic measures were compared. Age-group matching was attempted but was inexact because of limited availability of serum samples. Clinical and immunologic information was not available at the time of selection of control subjects; thus, selection bias due to these factors is unlikely. All control samples were tested anonymously.
Clinical and demographic details of subjects with vaccine failure. A standard questionnaire was sent to the physician for each subject with vaccine failure, and a copy of the hospital discharge summary was requested. The clinical information sought included the following: prematurity (!37-40 weeks of gestation), birth weight, genetic disorders, underlying medical conditions, and underlying immunologic abnormalities.
Immunologic testing. Immunoglobulin classes were measured in convalescent serum samples by nephelometry and IgG subclasses by radial immunodiffusion by use of monoclonal antibody kits. Age-stratified normal ranges for the United Kingdom, published by the National Supraregional Protein Reference Unit, were used to define class and subclass deficiency [9] . Standard ELISAs were performed for diphtheria and tetanus antibodies, as described elsewhere [10] .
Serologic testing for response to MenC disease. Serum samples, both acute (taken within 3 days of onset) and convalescent (taken 7 or more days after onset), were assayed as they were received by the HPA MRU, with the laboratory staff blinded as to the vaccination status. Titers of serum bactericidal antibody (SBA) to the standard C11 meningococcal strain (C:16: P1.7-1,1) were measured using pooled 3-or 4-week-old-baby rabbit complement (Pelfreeze Biologicals); SBA titers are expressed as the reciprocal of the final serum dilution causing у50% killing at 60 min [11] . SBA titers !4 were reported as 2 for computational purposes. MenC-specific IgG concentrations were measured using a standardized ELISA by a standard reference serum sample (CDC1992) assigned a value of 24.1 mg/L [12] . The lower limit of antibody detection was 0.1 mg/ L; results below this limit were reported as 0.05 mg/L for computational analyses. Antibody avidity was measured by an elution ELISA using the chaotropic agent thiocyanate [13] . The avidity index (AI) was derived by calculating the amount of thiocyanate required to reduce the absorbance in a given sample by 50%. Avidity was tested in subjects with antibody levels 10.6 mg/L; an AI of 50 was considered to be the lower limit of the assay. Because of limitations in available volumes of serum sample, not all samples tested for IgG could be tested for SBA or avidity.
Statistics. All data were collated and stored electronically at the HPA. Statistical analyses were performed using Stata (version 8; StataCorp). SBA titers in the acute samples were analyzed as a binary variable, !8 or у8, the latter being the putative correlate of protection [14, 15] ; all other variables were approximately normally distributed (once log transformed) and were analyzed as continuous variables. When comparing the subjects with vaccine failure and control subjects, proportions were compared using a x 2 test or Fisher's exact test, medians were compared using the Kruskal-Wallis test, and geometric means were compared using a t test on the log-transformed data. The comparison of AIs for acute samples was also assessed using the Kruskal-Wallis test because of the small sample size. When comparing antibody levels between subjects with vaccine failure and control subjects, multivariable logistic or normal error regression was used to adjust for the potentially confounding variables (1) age at onset and (2) interval between disease onset and blood sampling. In the subjects with vaccine failure, when looking at time since vaccination, an adjustment was also made for age at vaccination. Age at onset was divided into 3 age groups (!2 years, 2-5 years, and 15 years); time since vaccination was analyzed as a binary variable (!18 or у18 months); and age at vaccination was divided into 5 groups (!6 months, 6-11 months, 1-1.99 years, 2-4.99 years, and у5 years). Sampling intervals were analyzed as continuous variables and were calculated using the date of admission to hospital or the date of the first diagnostic sample if the date of symptom onset was not available.
RESULTS
Between January 2000 and December 2003, there were 465 subjects with confirmed MenC disease in the birth cohorts eligible for vaccination in England and Wales; vaccination history was obtained for 463 (99.4%). Of these, 387 subjects were unvaccinated at the time of disease onset, 53 met the definition for a confirmed MCC vaccine failure, and 22 were either incompletely vaccinated or presented within 10 days of vaccination (table 1) . Of the 22 excluded vaccinated subjects, 5 had onset within 10 days (range, 3-7 days) of their single scheduled dose (age range at admission, 1.86-17.42 years). Of the remaining 17 who were scheduled for 3 doses, 5 had onset within 10 days (range, 2-7 days) of the first dose, 8 had disease onset у10 days after their first dose, and 4 had disease onset у10 days after their second dose. The case fatality ratio among subjects with vaccine failure was 7.5% (4/53) , compared with 10.6% (41/387) among unvaccinated subjects. A total of 3 subjects with vaccine failure were reported from Northern Ireland and have been included in the present investigation of the mechanism of and risk factors for vaccine failure.
The 56 subjects with vaccine failure presented a median of 517 days (17 months) after completion of their vaccination course (range, 1.8-44 months). Eighteen of the subjects with vaccine failure were vaccinated routinely in infancy, and 38 were vaccinated in the catch-up campaign, of whom 3 received 2 doses between 5 and 12 months of age and 35 received 1 dose of vaccine 11 year of age (range of age at onset, 1.1-18.2 years; median age, 4.6 years). Analysis of the batch numbers of the vaccines received by the subjects with vaccine failure did not indicate any common batch problem (data not shown). Because the Wyeth vaccine was licensed first and was therefore the only preparation used in the early part of the program (when MenC incidence was at its height), the majority of subjects with vaccine failure had received this vaccine; therefore, comparisons between manufacturers were not possible.
Twenty-eight of the 56 vaccine failures were confirmed by PCR alone, and 28 were confirmed by culture with or without PCR. Of the culture-positive group, 24 (86%) had phenotypic characteristics (serotype 2a, PorA VR1 P1.5, or PorA VR2 P1.2) of ST-11 strains, compared with 214 (88%) of the 242 cultureconfirmed unvaccinated subjects.
Fifty-five unvaccinated subjects with confirmed MenC disease with onset between December 1999 and April 2002 were selected as control subjects. Twenty-five MenC cases were confirmed by PCR alone, and 30 were confirmed by culture with or without PCR. The demographic details of and serum samples available from the subjects with vaccine failure and the unvaccinated control subjects with MenC disease are shown in table 2. Two control subjects were from Northern Ireland.
Clinical details of subjects with vaccine failure. Clinical details were obtained for 52 (93%) of the 56 subjects with vaccine failure. No child had a history of immunosuppression. The only subject with vaccine failure with a noteworthy medical history was a 7-year-old who completed a course of radio-and chemotherapy for Wilm tumor 16 months before being admitted for meningococcal disease, by which time he was in remission. The tumor presented 2 years after MCC vaccination. Three children were born prematurely (34, 30, and 33 weeks of gestation, presenting at 11 years, 18 months, and 20 months, respectively; the second 2 were vaccinated in infancy). No attempt was made to collect clinical details in the unvaccinated control group. Immunologic investigation. Overall, there was no difference in proportions with immunoglobulin isotype or subclass deficiency between the subjects with vaccine failure and the unvaccinated control subjects (table 3). All subjects with vaccine failure who were tested for antibodies to tetanus had an anitbody level 10.01 IU/mL; 13 (65%) of 20 vaccinated subjects ( ), compared with 24 (86%) of 28 control subjects, had P p .09 a level 10.1 IU/mL, generally considered as protective, and geometric mean tetanus antibody concentrations were similar in both groups ( ). The geometric mean diphtheria an-P p .43 tibody concentration was 0.31 IU/mL (95% confidence interval [CI], 0.13-0.71 IU/mL) in the subjects with vaccine failure and 0.29 IU/mL (95% CI, 0.14-0.61 IU/mL) in the control subjects ( ; , adjusted for age). P p .93 P p .55
Serologic testing for response to MenC disease. In the subjects with vaccine failure, no significant differences were found in SBA titers, IgG levels, or AIs between those with onset within 18 months of the last dose ( ) and those with onset у18 n p 30 months since the last dose ( ), by use of a multivariable n p 26 analysis (data not shown). SBA titers, IgG levels, and AIs in acute and convalescent serum samples were compared between the subjects with vaccine failure and the unvaccinated control subjects, both by use of unadjusted and multivariable analysis (table 4). Of the 10 subjects with vaccine failure with an IgG concentration у0.6 mg/L in an acute serum sample, only 6 (60%) had sufficient volume remaining for avidity testing; the corresponding numbers for the control subjects were 18 and 9 (50%), respectively. Because there were very few subjects with both acute and convalescent results, analysis of results as paired samples was not possible.
In the multivariable analysis, after adjusting for age at admission and sampling interval, there was no difference in acute serogroup C SBA titers or serogroup C-specific IgG levels between the subjects with vaccine failure and the unvaccinated control subjects (table 4) . However, acute antibody avidity was significantly higher (by a factor of 3.2) in the subjects with vaccine failure than in the unvaccinated subjects ( ). P p .001 Convalescent SBA titers were significantly higher (by a factor of 6.1) in the subjects with vaccine failure ( ), and the P p .03 convalescent IgG concentration was also higher, albeit not significantly, by a factor of 2.3 ( ). The convalescent avidity P p .11 was not significantly different between the 2 groups (table 4). The multivariable analysis also showed that acute SBA titers, IgG levels, and AIs all increased with sampling interval (P p , , and , respectively), whereas no effect of .02 P p .002 P p .07 sampling interval on convalescent SBA titers, IgG levels, or AIs was seen ( , , and , respectively). Acute P p .16 P p .06 P p .58 IgG levels increased with age at onset ( ); convalescent P p .007 SBA titers and IgG levels, a swell as acute SBA titers, also tended to increase with age, but not significantly ( , , P p .09 P p .07 and , respectively). AIs did not depend on age ( P p .11 P p and for acute and convalescent, respectively). .38 P p .44 NOTE. Data are no. of subjects with indicated isotype or subclass deficiency/total no. of subjects with convalescent serum samples (%).
DISCUSSION
The impact of the MCC vaccination program has been substantial, with a 93% reduction in MenC cases by June 2004 [8] and only 53 vaccine failures identified in England and Wales in the first 4 years of the immunization program. Moreover, there has also been a decline in disease in unvaccinated children and adults, indicative of an indirect protective effect as a result of a reduction in nasopharyngeal carriage [16] . However, despite evidence from clinical trials that MCC vaccine induced immune memory [6] , the initial high level of direct protection was shown to decline subsequently, particularly in infants [5] . The present study confirms that the ability to generate a memory response to the capsular polysaccharide of MenC organisms, as evidenced by higher SBA titers in convalescent serum samples and higher IgG avidity in acute serum samples from subjects with vaccine failure, compared with those of unvaccinated subjects with MenC disease, does not necessarily confer protection. This is presumably because the booster response is not sufficiently rapid to prevent the invasion that usually occurs within a few days of colonization [17, 18] . Time since vaccination showed no statistically significant effects on acute or convalescent antibody responses in the subjects with vaccine failure. Thus, there was no evidence that the mechanism of vaccine failure was different in early and late onset cases.
The immunologic investigations did not suggest an excess of inherent immunodeficiencies in the subjects with vaccine failure, compared with those in control subjects. Response to conjugate vaccines in infancy relies on the recruitment of CD4 T helper cells, which both enhance the production of antibody (particularly IgG1 and IgG3) by B cells and result in the development of memory B cells. Such subclass deficiencies did not occur more frequently in subjects with vaccine failure than in control subjects. IgG2 deficiency, which would be expected to result in an inability to respond to polysaccharide antigens, was found in 5% of subjects with vaccine failure, compared with 13% of unvaccinated subjects with MenC disease, and is consistent with ranges published for children. We have not attempted to measure complement deficiencies in the subjects, and this is an area that merits further investigation because it is a well-established, albeit rare, risk factor for meningococcal disease [19, 20] .
There were 4 subjects with vaccine failure with a clinical history suggestive of possible impaired immune responses: 1 child with a history of immunosuppression and 3 with a history of prematurity, 2 of whom (10%) were among the 21 subjects with vaccine failure vaccinated at !1 year of age. This proportion is similar to that found in a study of Haemophilus influenzae type b (Hib) conjugate vaccine failures, in which 12% of those vaccinated at !1 year of age were premature [21] . Hib vaccine is less immunogenic in premature than term infants under the UK accelerated schedule [22, 23] , but SBA responses to MCC vaccine are similar [24, 25] . The relevance of the finding of 2 premature infants among the subjects with vaccine failure who were vaccinated in the first year of life is therefore uncertain.
All subjects with vaccine failure who were tested for antibodies to tetanus had antibody levels 10.01 IU/mL-a frequently used marker of a normal ability to respond to vaccinations in children. Moreover, there were no significant differences in antitetanus geometric mean titers or proportions 10.1 IU/mL between subjects with vaccine failure and control subjects, nor were there any differences between these groups in diphtheria antibody levels. The latter is perhaps surprising because all subjects with vaccine failure had received a CRM 197 -containing vaccine that, in primed children, boosts diphtheria antibody levels to a similar degree as a diphtheria toxoid vaccine [10] .
The study was limited by the number of serum samples available from subjects with vaccine failure and the adequacy of age matching of the control subjects. However, there was sufficient overlap in age at onset and interval to sampling to allow valid comparisons to be made after adjusting for the effect of these factors in the multivariable analysis. Overall SBA titers and IgG levels in postdisease serum samples tended to increase with age, consistent with the age dependency of the response to MCC vaccine [10] . The higher median age, if not adjusted for, would have been expected to lead to a higher booster-type response in the control subjects, whereas the unadjusted response in the subjects with vaccine failure was higher (table 4). In the analyses of acute avidity, the subset of samples available for testing was small and was biased toward later sample Table 4 . Effect of vaccination status on serogroup C serum bactericidal antibody (SBA) titers, IgG levels, and avidity indices (AIs) in acute and convalescent serum samples from subjects with vaccine failure (F) and control subjects (C). collection in the control subjects. Because the multivariable analysis showed that acute AI increased with sampling interval, this selection bias would tend to cause higher avidity in control subjects than in subjects with vaccine failure, and yet the reverse was true in the unadjusted analyses.
The proportion of subjects with vaccine failure without levels of antibody considered to be protective (SBA titer, у8) [14, 15] for acute serum samples was similar to that in the unvaccinated subjects (59% and 65%, respectively). In the minority who had SBA titers у18 in their acute sample, this does not necessarily indicate the development of disease despite protective levels at the time of disease onset. Information on the precise day of onset was difficult to obtain and was often based on the date of admission to hospital or, failing this, the date of the first diagnostic sample. Given the delays that may occur between disease onset and admission to hospital or initial microbiological investigation, it is possible that the actual interval between symptom onset and sampling was longer than that calculated using admission or investigation dates. In the multivariable analysis, SBA titers in acute serum samples increased significantly with sampling interval, confirming that accurate definition of the date of symptom onset is important.
Despite the evidence of priming in the vaccinated children, case fatality ratios were similar in subjects with vaccine failure and unvaccinated subjects, suggesting that this priming was not able to prevent death. Strains with certain phenotypic characteristics (C:2a), associated with strains from the ST-11 clonal complex, seem to produce a higher case fatality [26] , but the proportion of cases due to C:2a infection was similar in subjects with vaccine failure and unvaccinated subjects with MenC disease.
The marked decline in effectiveness of MCC vaccine after infant immunization at 2-4 months of age has also been seen with the Hib conjugate vaccine [27] , even in infant cohorts that have been vaccinated with the highly immunogenic combination vaccines containing whole-cell pertussis components [28] . Moreover, investigation of Hib vaccine failures has also suggested that these have evidence of immune memory rather than being primary vaccine failures [29] . Conjugate vaccine failures thus occur in children who have been primed and in whom immune memory can be demonstrated. As with MCC vaccine, Hib vaccine effectiveness and protective antibodies persist longer in those vaccinated after the first year of life [30, 31] . This suggests that protection may be more reliant on circulating antibodies at the time of exposure than on the ability to mount a booster response.
These data have wider implications for vaccination schedules and licensing of conjugate vaccines. On the basis of the UK data, booster doses after the fist year of life are now recommended by the European Medicines Evaluation Agency for both Hib and MCC vaccines. A booster dose has also been included in the schedule for the 7-valent pneumococcal conjugate vaccine, which was introduced in the United Kingdom in September 2006, at the same time as the Hib and MCC boosters [32] . Reliance on evidence of avidity maturation and a booster response to plain polysaccharide can no longer be regarded as an immunologic correlate of long-term protection for conjugate vaccines, and more studies that focus on antibody persistence as a putative correlate are necessary.
